- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02394886
Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
October 15, 2015 updated by: Anterogen Co., Ltd.
A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
This is a phase I open-label study to evaluate the safety of ALLO-ASC-DFU in diabetic foot ulcers patients.
ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.
Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.
Study Overview
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is between 18 and 80 years of age.
- Subject is diagnosed with Type I or Type II diabetes.
- Subjects who have a wound defined as diabetic foot ulcer presence for more than 4 weeks, but not present for more than 54 weeks at the screening visit.
- Foot ulcer located below the malleoli on plantar or dorsal surface of the foot and ulcer size is between 1 cm^2 and 25 cm^2.
- Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule.
- Ulcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made of primarily vascularized tissue.
- 0.7 < Ankle Brachial Index (ABI) < 1.3.
- Subject is able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria:
- Ulcer is of non-diabetic pathophysiology.
- Gangrene is present on any part of the affected foot.
- Ulcer is over an active Charcot deformity.
- The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.
- The longest dimension of the Index Ulcer exceeds 5 cm at the screening visit.
- Subject is Human Immunodeficiency Virus (HIV) positive.
- Subjects with severe hepatic deficiencies.
- Subjects with a glycated hemoglobin A1c (HbA1c) level of > 12%.
- Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.
- Subjects requiring intravenous (IV) antibiotics to treat the index wound infection.
- Subjects who are currently receiving dialysis.
- Subjects who are pregnant or breast-feeding.
- Subjects who are unwilling to use an "effective" method of contraception during the study.
- Current evidence of osteomyelitis, cellulitis, or other evidence of infection including pus drainage from the wound site.
- Subjects who have a clinically relevant history of alcohol or drugs abuse.
- Subject's blood sugar is > 450 mg/dL at postprandial.
- Subjects who are not able to understand the objective of this study or to comply with the study requirements.
- Subjects who are considered to have a significant disease which can impact the study by the investigator.
- Subjects who are considered not suitable for the study by the investigator.
- Subjects who have a history of surgery for malignant tumor within the last five years (except carcinoma site).
- Subjects who are currently or were enrolled in another clinical study within 60 days of screening.
- Subjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.
- Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALLO-ASC-DFU
ALLO-ASC-DFU treatment with conventional care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: up to 4 weeks
|
up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound size and depth measurement
Time Frame: baseline and 1, 2, 4 weeks
|
Evaluation of the improvement of wound measured by size and depth, and examines the change for 4 weeks period.
|
baseline and 1, 2, 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joon Pio Hong, MD, PhD, Asan Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
March 3, 2015
First Submitted That Met QC Criteria
March 17, 2015
First Posted (Estimate)
March 20, 2015
Study Record Updates
Last Update Posted (Estimate)
October 16, 2015
Last Update Submitted That Met QC Criteria
October 15, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALLO-ASC-DFU-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on ALLO-ASC-DFU
-
Anterogen Co., Ltd.Completed
-
Anterogen Co., Ltd.RecruitingDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.RecruitingDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedDystrophic Epidermolysis BullosaKorea, Republic of
-
Anterogen Co., Ltd.CompletedDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedClinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot UlcersDiabetic Foot UlcerKorea, Republic of
-
Anterogen Co., Ltd.CompletedBurn InjuryKorea, Republic of
-
Anterogen Co., Ltd.CompletedDystrophic Epidermolysis BullosaKorea, Republic of
-
Anterogen Co., Ltd.CompletedBurnKorea, Republic of